Boston Scientific's Obsidio embolic occluded all target vessels in 125-patient U.S. registry
Boston Scientific's Obsidio embolic occluded 100% of target vessels in the 125-patient OCCLUDE registry; the FDA approves Infilbray for type 3 Gaucher disease and Livsayis, the first siRNA therapy for myasthenia gravis.
U.S. reported to lose measles elimination status after 26 years
The U.S. is reported to have lost its measles elimination status after 26 years; CMS lets states delay Medicaid work-requirement enforcement to mid-2027 and the FDA approves a new bladder cancer regimen.